"Management and Treatment of Patients with Cystic fibrosis (CF)

Size: px
Start display at page:

Download ""Management and Treatment of Patients with Cystic fibrosis (CF)"

Transcription

1 "Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March 1 st 2017

2 CF- Introduction CF is the most common serious genetic disease Previously patients died in early infancy and childhood For those born in 2000, the UK CF data estimate survival greater than 50 years Advances in CF care are largely responsible for the improved lifespan New therapies directed towards underlying defect promise to open a new era of CF therapeutics

3 CF Median Life Expectancy Median Survival Age (Years) Year

4 Genetics of CF- the CFTR gene Autosomal-recessive Inheritance In 1989 the CFTR gene was discovered The CFTR gene resides on the long arm of chromosome 7 More than 1800 mutations in the CFTR gene associated with disease have been reported The most common mutation- DelF508 (75%)

5 H 2 O Cl - Na + H 2 O CFTR Na + Cl - ENaC Cl - Cl - camp Ca 2+ K + 2Cl - K + Na + K + Na +

6 CFTR gene mutation CFTR defect Electrolyte transport abnormalities Excesive/abnormal mucus production Bacterial Infection Neutrophil dominated Inflammation Progressive lung damage Death

7

8 Respiratory Presentations of CF Chronic cough Recurrent/ chronic bronchitis or pneumonia Severe wheezing/ hyperinflation Tachypnea/ retractions Atelectasis Hemoptysis Pneumothorax Bronchiectasis Staph/ Pseudomonas colonization in the respiratory tract Chronic pansinusitis Nasal polyps Clubbing

9 Incidence of Major Airway Pathogens by Patient Age Cystic Fibrosis Patient Registry 2010

10 Pseudomonas aeruginosa in the CF lungs Chronic P. aeruginosa (PA) lung infection is the cause of much of the morbidity and most of the mortality in CF patients ~80% of CF adults have chronic PA infection; once a chronic infection is established, it is very difficult to eradicate Aggressive early eradication therapy have to be initiated as soon as the pathogen is detected, which can delay the onset of chronic infection

11 Risk of eradication failure increased by with delayed CF diagnosis Successful eradication increased with each additional sputum culture taken Delayed detection of PA infection leading to delayed treatment and growth of multiresistant organisms is associated with eradication failure M. Cohen-Cymberknoh et al, Journal of Cystic fibrosis 2016

12 Gastrointestinal Presentations of CF Meconium ileus (~15%) Prolonged neonatal jaundice Steatorrhea Rectal prolapse Mucoid impacted appendix Recurrent intussusception Recurrent pancreatitis Liver disease ~30%- fatty liver, focal/multilobar biliary cirrhosis Distal Intestinal Obstruction Syndrome (DIOS)

13 Metabolic Presentations of CF Salty taste Failure to thrive Hypoproteinemia, edema Vitamin A, E, D deficiency Hemolytic anemia (Vitamin E deficiency) Salt depletion - Metabolic alkalosis Azoospermia/CBAVD- male infertility (98%)

14 CF diagnosis NPD One or more characteristic clinical features of CF or Sweat test Gold standard diagnose CF a Results: family history of positive Cl > 60 mmol/l- neonatal positive screening Cl < 40 mmol/l- negative Cl = mmol/l- borderline Together with: Abnormal sweat chloride values on 2 occasions or abnormal Nasal Potential Difference (NPD) identification of two (CFTR) mutations CF diagnostic consensus, Rosenstein et al. J Pediatr 1998

15 Zielenski, Respiration 2000 Spectrum of phenotypes

16 Classic and non-classic CF Early pulmonary involvement (>95%) (CBAVD) (CBAVD)

17 * * * * 21 y.o. male CF-PI patient 21 y.o. male CF-PS patient Simanovsky and Cohen-Cymberknoh et al, Chest 2013

18 A more negative correlation between FEV 1 % and Age in the CF-PI group No correlation between FEV 1 % and %BMI in the CF-PS group a comparison of disease characteristics for (PCD and) CF should distinguish between CF-PI and CF-PS as different entities Good correlation between TBS and Age in the CF-PI and CF-PS groups Good correlation between FEV 1 % vs. TBS in the CF-PI and CF-PS groups M. Cohen-Cymberknoh, Chest 2014

19 Improving Quality of Life

20 The 10 Golden Rules of CF Care 1.Maintain good nutrition and correct nutritional deficiencies 2.Daily chest physiotherapy 3.Enhance mucociliary clearance (inhaled hypertonic saline & Pulmozyme) 4.Avoid and early treat new acquisition of pseudomonas infection 5.Suppression of chronic pseudomonas infection (inhaled antibiotics) 6.Early and aggressive treatment of pulmonary exacerbation 7.Anti-inflammatory therapy 8.Early identification and treatment of complications 9.Centered care with frequent regular visits 10.Strict adherence to all the above therapies Cohen-Cymberknoh et al, ERJ 2014

21 Class III Regulation (G551D) R Five Class CFTR Mutations Class II Protein processing (DelF508) R Cl - A new type of individualized treatment R X in R CF: Class IV Impaired Conductance (R1152H) Class I No protein synthesis (W1282X) Cl - R Class V Mutation class specific therapy Reduced number

22 Classes of CFTR Mutations Normal I II III IV V No Block in Block in Altered synthesis processing regulation conductance G542X W1282X F508del G551D R117H D1152H Reduced synthesis kbC >T 5T A455E 12% 87% 5% 5% 5% Premature Stop Mutations 60% in Ashkenazi Jewish patients

23 Normal Flow of Genetic Information Results in Full-Length Protein Production Normal Translation Normal Stop Codon Ribosomes Amino acid Protein mrna Full-length Protein

24 Nonsense Mutation Halts the Flow of Genetic Information and Results in Truncated Protein Production Premature Termination Nonsense (Premature Stop) Codon Normal Stop Codon Protein mrna Truncated Protein

25 Wilschanski et al. NEJM 2003

26 Ataluren Has Been Designed to Overcome Nonsense Mutations Ataluren Nonsense (Premature Stop) Codon Normal Stop Codon YIELD Protein mrna Fulllength Protein

27 Mean relative change in percent-predicted FEV 1 from baseline to week 48 Ataluren is already registered for patients with Duchenne Muscular Dystrophy carrying nonsense mutations Kerem E et al. Lancet Respir Med. 2014

28 Classes of CFTR Mutations Normal I II III IV V No Block in Block in Altered synthesis processing regulation conductance G542X W1282X F508del G551D R117H D1152H Reduced synthesis kbC >T 5T A455E 12% 87% 5% 5% 5% CFTR gating mutations CFTR that not open and close properly

29 Ramsey, B et al. New Engl J Med 2011

30 Ivacaftor (Kalydeco), a CFTR potentiator for Class 3 mutations Improves sweat chloride levels Improves lung function Improves weight Improves time-to-first pulmonary exacerbation Improves OGTT and insulin secretion 2012

31 Jerusalem Marathon 10 km March 2016

32 Classes of CFTR Mutations Normal I II III IV V No Block in Block in Altered synthesis processing regulation conductance G542X W1282X F508del G551D R117H D1152H Reduced synthesis kbC >T 5T A455E 12% 87% 5% 5% 5%

33 F508del Results in Defective Processing, Defective Gating, and Reduced Surface Stability The F508del mutation affects the processing and trafficking of the resultant CFTR proteins Golgi The result is little to no CFTR protein delivered to the apical cell surface The small amount of F508del-CFTR that may reach the apical cell surface has reduced function and accelerated turnover Proteasome ER Nucleus Wang XR, Li C. Biomolecules 2014

34 Increased Activity of DF508 CFTR with Lumacaftor in Combination with Ivacaftor + CFTR potentiator (Ivacaftor) F508del-CFTR + CFTR corrector (Lumacaftor) + CFTR potentiator (Ivacaftor) F508del-CFTR Chloride Transport (% of normal CFTR) No drug P= P= ivacaftor Alone (3 μμm) P= lumacaftor Alone (3 μμm) P= lumacaftor + ivacaftor (3μμM + 3μμM) Modified from Van Goor et al. PNAS 2011

35 2015

36 Elborn et al. ECFS 2015 ppfev 1 : Up to 48 Weeks of Treatment

37 Analysis of Pulmonary Exacerbations: Pooled

38 Our Orkambi experience One patient homozygous for Phe508del 40 y/o, married + 3 Severe lung disease, CF-related diabetes 60 ppfev1 before and after Orkambi Orkambi months

39 Number of patients with CF in Israel n= Males / Females 56% / 44% Soroka Hadassah Rambam Schneider Carmel Sheba

40 Pulmonary function (FEV 1 median) in Israel %

41 Percentage of adult CF patients in Israel Patients 18y= % 58 58% EU 51.8%

42 CF Survival is Improving Orkambi Dorothy Andersen, 1938 Restore CFTR function CFF Drug Pipeline

43 Our patients and families

44

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic

More information

Cystic Fibrosis Foundation Patient Registry 2013

Cystic Fibrosis Foundation Patient Registry 2013 5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical

More information

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology

More information

Cystic fibrosis: hitting the target

Cystic fibrosis: hitting the target Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas

More information

Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy

Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive

More information

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives. Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex

More information

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =

More information

The Future of CF Therapy

The Future of CF Therapy The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy

More information

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41

More information

Respiratory Pharmacology: Treatment of Cystic Fibrosis

Respiratory Pharmacology: Treatment of Cystic Fibrosis Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart

More information

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other

More information

Cystic Fibrosis the future

Cystic Fibrosis the future Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics

More information

Evaluation of Patients with Diffuse Bronchiectasis

Evaluation of Patients with Diffuse Bronchiectasis Evaluation of Patients with Diffuse Bronchiectasis Dr. Patricia Eshaghian, MD Assistant Clinical Professor of Medicine Director, UCLA Adult Cystic Fibrosis Affiliate Program UCLA Division of Pulmonary

More information

Cystic Fibrosis Diagnosis and Treatment

Cystic Fibrosis Diagnosis and Treatment Cystic Fibrosis Diagnosis and Treatment Financial Disclosures Personal financial relationships with commercial interests relevant to medicine, within the past 3 years: NJH site PI for AstraZeneca. As faculty

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics

More information

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016 Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy Susanna A McColley, MD Associate Chief Research Officer Stanley Manne Children s Research Institute

More information

Enabling CF Therapeutic Development

Enabling CF Therapeutic Development Enabling CF Therapeutic Development PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs No Disclosures Cystic Fibrosis In 1955 In 1955 most children with CF did not live long enough

More information

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

A Quick Guide to the. I507del. Mutation CFTR SCIENCE A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum

More information

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there

More information

Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.

Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. 1938 OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children. : The beginning May 1938: 49 cases 25 20 15 Nos of cases 10 5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Age

More information

A Genetic Approach to the Treatment of Cystic Fibrosis

A Genetic Approach to the Treatment of Cystic Fibrosis A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March

More information

HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF

HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF Peter D. Sly MBBS, MD, FRACP, DSc OUTLINE Goals of CF treatment Drivers of early disease neutrophilic inflammation oxidative stress

More information

Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel

Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -

More information

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG

More information

Targeted therapies to improve CFTR function in cystic fibrosis

Targeted therapies to improve CFTR function in cystic fibrosis Brodlie et al. Genome Medicine (2015) 7:101 DOI 10.1186/s13073-015-0223-6 REVIEW Targeted therapies to improve CFTR function in cystic fibrosis Malcolm Brodlie 1*, Iram J. Haq 2, Katie Roberts 2 and J.

More information

Kalydeco. Kalydeco (ivacaftor) Description

Kalydeco. Kalydeco (ivacaftor) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco

More information

A review of Cystic Fibrosis

A review of Cystic Fibrosis A review of Cystic Fibrosis Jennifer Landry md F.R.C.P.(C) Pulmonary & Critical Care Medicine McGill University Health Center Cystic Fibrosis One of the most common lethal inherited AR disorders in the

More information

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER February 21, 2014 U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in Eight

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf

More information

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)?

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)? Module I: Introduction to the disease Give a brief introduction to the disease, considering the following: the symptoms that define the syndrome, the range of phenotypes exhibited by individuals with the

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex

More information

Oral Cystic Fibrosis Modulators

Oral Cystic Fibrosis Modulators Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate

More information

Cystic Fibrosis Update

Cystic Fibrosis Update Cystic Fibrosis Update More than Decades of Discovery Dr. Raj Padman Professor of Pediatric TJU Board certified in Pediatrics, Pulmonology, and Sleep Medicine Dupont, Kosciusko Community, Lutheran, Rehabilitation,

More information

FACTS ABOUT. Cystic Fibrosis. What Is Cystic Fibrosis. What Are the Signs and Symptoms of CF?

FACTS ABOUT. Cystic Fibrosis. What Is Cystic Fibrosis. What Are the Signs and Symptoms of CF? FACTS ABOUT Cystic Fibrosis What Is Cystic Fibrosis Cystic fibrosis (CF) is a chronic, progressive, and frequently fatal genetic (inherited) disease of the body s mucus glands. CF primarily affects the

More information

PA Update: Oral Cystic Fibrosis Modulators

PA Update: Oral Cystic Fibrosis Modulators Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Disclosures. Learning Objectives. What is Cystic Fibrosis? Background

Disclosures. Learning Objectives. What is Cystic Fibrosis? Background 39 th National Conference on Pediatric Health Care March 19-22, 2018 CHICAGO Disclosures The Vision and the Journey of Cystic Fibrosis: Newborn Screening to Breakthrough Therapy March 20, 2018 Cynthia

More information

Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL

Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Objectives: At the end of the presentation the listeners will Be able to describe neonatal

More information

Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis

Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis Focus on (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Autosomal recessive, multisystem

More information

CF: Understanding the Biology Curing the Disease

CF: Understanding the Biology Curing the Disease CF: Understanding the Biology Curing the Disease Scott H. Donaldson, MD Associate Professor of Medicine Director, Adult CF Care Center University of North Carolina at Chapel Hill Defining the path Drilling

More information

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR

More information

Orkambi. Orkambi (lumacaftor/ivacaftor) Description

Orkambi. Orkambi (lumacaftor/ivacaftor) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.06 Subject: Orkambi Page: 1 of 6 Last Review Date: November 30, 2018 Orkambi Description Orkambi (lumacaftor/ivacaftor)

More information

Cystic Fibrosis. Presented by: Chris Belanger & Dylan Medd

Cystic Fibrosis. Presented by: Chris Belanger & Dylan Medd Cystic Fibrosis Presented by: Chris Belanger & Dylan Medd Outline What is Cystic Fibrosis? Signs, Symptoms & Diagnosis Who does it effect? General effects on daily life Managing Cystic Fibrosis Exercise

More information

Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses

Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses Changes in the management of children with Cystic Fibrosis Caroline Murphy & Deirdre O Donovan CF Nurses What Is Cystic Fibrosis? Cystic fibrosis (CF) is an inherited chronic disease that primarily affects

More information

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR

More information

Chapter 3 The Role of Nutrition in CF Care

Chapter 3 The Role of Nutrition in CF Care Chapter 3 The Role of Nutrition in CF Care S. King, N. Saxby & N. Sander Cystic fibrosis is the most common lethal autosomal recessive genetic condition affecting Caucasians 186,187. Over 3500 Australians

More information

Palliative and Supportive Care in Cystic Fibrosis

Palliative and Supportive Care in Cystic Fibrosis Palliative and Supportive Care in Cystic Fibrosis Dr William Flight Consultant in Respiratory Medicine Oxford Adult Cystic Fibrosis Centre 27 th January 2017 Overview 1. Cystic Fibrosis Clinical Aspects

More information

Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?

Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis? Names: Date: Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis? Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the

More information

Briefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee

Briefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee FDA Advisory Committee Briefing Materials Page 1 of 157 Briefing Document FDA Pulmonary - Allergy Drugs Advisory Committee Ivacaftor for the Treatment of Cystic Fibrosis in Patients Age 6 Years and Older

More information

Cystic Fibrosis. Parkland College. Monica Rahman Parkland College. Recommended Citation

Cystic Fibrosis. Parkland College. Monica Rahman Parkland College. Recommended Citation Parkland College A with Honors Projects Honors Program 2013 Cystic Fibrosis Monica Rahman Parkland College Recommended Citation Rahman, Monica, "Cystic Fibrosis" (2013). A with Honors Projects. 98. http://spark.parkland.edu/ah/98

More information

Cystic Fibrosis Care at the University of Florida

Cystic Fibrosis Care at the University of Florida Cystic Fibrosis Care at the University of Florida Objectives To introduce you to the University of Florida CF Center To review center specific data for the UF pediatric CF Center To review current status

More information

Fungal (Aspergillus and Candida) infections in Cystic fibrosis

Fungal (Aspergillus and Candida) infections in Cystic fibrosis Fungal (Aspergillus and Candida) infections in Cystic fibrosis Malena Cohen-Cymberknoh, MD CF Center Hadassah-Hebrew University Medical Center Jerusalem, Israel Israeli Annual CF Conference, Herzlyia,

More information

A Case of Cystic Fibrosis

A Case of Cystic Fibrosis Name(s) Date A Case of Cystic Fibrosis Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the day. The baby's parents had brought young Zoey to the emergency

More information

Class Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators

Class Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

CF: Information for Case Managers. Cindy Capen MSN, RN Pediatric Pulmonary Division University of Florida

CF: Information for Case Managers. Cindy Capen MSN, RN Pediatric Pulmonary Division University of Florida CF: Information for Case Managers Cindy Capen MSN, RN capencl@peds.ufl.edu Pediatric Pulmonary Division University of Florida About your speaker 25+ years in pulmonary Coordinator for CF Center and CF

More information

Overview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist

Overview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist Overview of Cystic fibrosis in children Apeksha Sathyaprasad, MD Pediatric pulmonologist No conflicts of interest OBJECTIVES Review pathophysiology of pulmonary disease in cystic fibrosis Review diagnostic

More information

Recently, the cystic fibrosis (CF) community celebrated the 25th

Recently, the cystic fibrosis (CF) community celebrated the 25th focused review A new era of personalized medicine for cystic fibrosis at last! Bradley S Quon MD MSc FRCPC 1,2, Pearce G Wilcox MD FRCPC 1,2 BS Quon, PG Wilcox. A new era of personalized medicine for cystic

More information

Cystic Fibrosis. History of Cystic Fibrosis. History of Cystic Fibrosis. Cystic Fibrosis. Salty Kiss

Cystic Fibrosis. History of Cystic Fibrosis. History of Cystic Fibrosis. Cystic Fibrosis. Salty Kiss Cystic Fibrosis History of Cystic Fibrosis Salty Kiss Dr Marleen Moens Revalidatiecentrum voor kinderen en jongeren, respiratoire afdeling UZ Gasthuisberg, mucoteam Leuven 1938 Anderson: cystic fibrosis

More information

Michael Wilschanski Pediatric Gastroenterology, Hadassah Medical Organization Jerusalem, Israel

Michael Wilschanski Pediatric Gastroenterology, Hadassah Medical Organization Jerusalem, Israel Recurrent Acute Pancreatitis in Israeli, Children Michael Wilschanski Pediatric Gastroenterology, Hadassah Medical Organization Jerusalem, Israel ISPGHAN EILAT FEBRUARY RY 2013 Etiologies of recurrent/chronic

More information

**Cystic Fibrosis** Notes :

**Cystic Fibrosis** Notes : **Cystic Fibrosis** Notes : - the slides are included in the lecture. - everything in Italic is just important things from the old lecture. - It s easy lecture, even it seems long.. GOOD LUCK Cystic fibrosis

More information

We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis

We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward

More information

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative

More information

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal 1 2 3 Cystic fibrosis is a rare life-long genetic disease that affects approximately 4,000 people in Canada and about 70,000 worldwide regardless of race or ethnicity but is more common in Caucasians 1,2

More information

Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients?

Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients? CF Europe Meeting Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients? Margarida D Amaral Brussels, 13 June 2015 The CF Pathogenesis Cascade 2 Defective CF Genes Deficient CFTR

More information

At-A-Glance report 2014

At-A-Glance report 2014 At-A-Glance report 14 Cystic Fibrosis in Europe Facts and Figures 14 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic

More information

Recent advances in the management of cystic fibrosis

Recent advances in the management of cystic fibrosis REPORT Recent advances in the management of cystic fibrosis DANNY BUCKLAND More effective management programmes and treatments mean that life expectancy for people with cystic fibrosis is improving. This

More information

At-A-Glance report 2013

At-A-Glance report 2013 At-A-Glance report 213 Cystic Fibrosis in Europe Facts and Figures 213 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic

More information

10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis

10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).

More information

Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis

Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis CME/CNE/CPE Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis Course Director Jerry Nick, MD National Jewish Health University of Colorado Denver,

More information

CYSTIC FIBROSIS Risk Factors Epidemiology Pathogenesis Defective protein synthesis (10%) Abnormal protein folding, processing & trafficking

CYSTIC FIBROSIS Risk Factors Epidemiology Pathogenesis Defective protein synthesis (10%) Abnormal protein folding, processing & trafficking CYSTIC FIBROSIS Risk Factors Caucasian Family history of CF Infection Exposure to allergens and tobacco Epidemiology Carrier frequency of 1 in 25 for Caucasians The most common lethal genetic disease affecting

More information

Symdeko. Symdeko (tezacaftor and ivacaftor) Description

Symdeko. Symdeko (tezacaftor and ivacaftor) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.10 Subject: Symdeko Page: 1 of 5 Last Review Date: June 22, 2018 Symdeko Description Symdeko (tezacaftor

More information

Atypical cystic fibrosis: from the genetic causes to current and future treatments

Atypical cystic fibrosis: from the genetic causes to current and future treatments Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2016 Atypical cystic fibrosis: from the genetic causes to current and future treatments Quinn,

More information

Brand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated

Brand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated Brand Name: Kalydeco Generic: ivacaftor Manufacturer 1 : Vertex Pharmaceuticals Incorporated Drug Class 2,3 : Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator Uses: Labeled Uses 1,2,3,4,5

More information

Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)

Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations) Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations) Reference: NHS England: A01/P/c NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and

More information

National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008

National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008 Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Chronic lung diseases in children Simple choice 1. Finger clubbing is not characteristic for: a) Diffuse bronchiectasis b) Cystic fibrosis c)

Chronic lung diseases in children Simple choice 1. Finger clubbing is not characteristic for: a) Diffuse bronchiectasis b) Cystic fibrosis c) Chronic lung diseases in children Simple choice 1. Finger clubbing is not characteristic for: a) Diffuse bronchiectasis b) Cystic fibrosis c) Bronchiolitis obliterans d) Complicated acute pneumonia e)

More information

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically

More information

A Cure for All: Leaving No One Behind. Assuring Effective Therapies for All Patients with Cystic Fibrosis

A Cure for All: Leaving No One Behind. Assuring Effective Therapies for All Patients with Cystic Fibrosis A Cure for All: Leaving No One Behind Assuring Effective Therapies for All Patients with Cystic Fibrosis Topics for Today s Presentation Demographics of the CF patient population in the modulator era

More information

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM Pulmonary surfactant Pulmonary surfactant is (phospholipoprotein) complex

More information

Class Update: Oral Cystic Fibrosis Modulators

Class Update: Oral Cystic Fibrosis Modulators Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Caregiver burden and quality of life of parents of young children with cystic fibrosis

Caregiver burden and quality of life of parents of young children with cystic fibrosis Caregiver burden and quality of life of parents of young children with cystic fibrosis Professor Patricia Fitzpatrick 1 S George 1, R Somerville 1, B Linnane 2, C Fitzgerald 1 1 UCD School of Public Health,

More information

FOR GENERAL PRACTITIONERS

FOR GENERAL PRACTITIONERS INFORMATION PACK FOR GENERAL PRACTITIONERS Presented by 2 CONTENTS Chapter Page No 1. What is Cystic Fibrosis (CF)?... 5 Definition Symptoms The Digestive System Signs & Symptoms Breast Feeding & Cystic

More information

UNDERSTANDING CYSTIC FIBROSIS

UNDERSTANDING CYSTIC FIBROSIS UNDERSTANDING CYSTIC FIBROSIS INTRODUCTION Cystic fibrosis is a chronic disease that affects the respiratory and gastrointestinal systems. People with cystic fibrosis have a genetic defect of the lungs

More information

Modulator Treatments for Cystic Fibrosis: Effectiveness and Value

Modulator Treatments for Cystic Fibrosis: Effectiveness and Value Modulator Treatments for Cystic Fibrosis: Effectiveness and Value Draft Evidence Report March 15, 2018 Prepared for: Institute for Clinical and Economic Review, 2018 AUTHORS: ICER Staff/Consultants Ethan

More information

Cystic fibrosis: From the gene to the disease

Cystic fibrosis: From the gene to the disease Cystic fibrosis: From the gene to the disease Christiane Knoop, MD, PhD Institut de Mucoviscidose de l ULB Hôpital Erasme christiane.knoop@erasme.ulb.ac.be Cystic fibrosis «The infant that tastes of salt

More information

PATIENT EDUCATION. Cystic Fibrosis Carrier Testing

PATIENT EDUCATION. Cystic Fibrosis Carrier Testing PATIENT EDUCATION Cystic Fibrosis Carrier Testing Introduction Cystic fibrosis carrier testing before or during pregnancy can help determine your risk of having a child with cystic fibrosis. This information

More information

INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE

INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE Hannah Blau MBBS Pulmonary Institute and Graub CF Center SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL Chipap 18 th February 2015 Inhaled antibiotic therapy:

More information

Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)

Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England: 16029/P NHS England INFORMATION READER BOX Directorate Medical Operations and

More information

Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)

Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England E03X05/01 Information Reader Box (IRB) to be inserted on inside

More information

Advances in CF therapies and their effect on GI manifestations. Presenter Disclosure Daniel Gelfond, MD Relationship related to this presentation

Advances in CF therapies and their effect on GI manifestations. Presenter Disclosure Daniel Gelfond, MD Relationship related to this presentation Advances in CF therapies and their effect on GI manifestations Daniel Gelfond, MD University of Rochester WNY Pediatric Gastroenterology Presenter Disclosure Daniel Gelfond, MD Relationship related to

More information

Opening Doors to CF Clinical Research: Change is Coming

Opening Doors to CF Clinical Research: Change is Coming Opening Doors to CF Clinical Research: Change is Coming Disclosures Contracts with sponsors for clinical trials conducted at UNC-Chapel Hill: CFFT NIH/NHLBI AbbVie Inc. Aptalis Pharma US, Inc. Janssen

More information

Cystic Fibrosis. Advances and Asian Perspective Dr AS Paul 13 October 06

Cystic Fibrosis. Advances and Asian Perspective Dr AS Paul 13 October 06 Cystic Fibrosis Advances and Asian Perspective Dr AS Paul 13 October 06 Cystic Fibrosis An Overview Asian Perspective Advances Cystic Fibrosis An Overview Epidemiology and Pathogenesis Most common severe

More information

A Quick Guide to the G A. Mutation CFTR SCIENCE

A Quick Guide to the G A. Mutation CFTR SCIENCE A Quick Guide to the 1717-1G A Mutation FR SIENE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of FR activity is the underlying cause of cystic fibrosis (F) 1 Spectrum of Phenotypes

More information

Cystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus

Cystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus Eur Respir Rev 2013; 22: 127, 66 71 DOI: 10.1183/09059180.00008512 CopyrightßERS 2013 REVIEW Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Isabelle Sermet-Gaudelus ABSTRACT:

More information

Cystic Fibrosis. Information for Caregivers

Cystic Fibrosis. Information for Caregivers Cystic Fibrosis Information for Caregivers Arkansas Children s Hospital is an accredited Cystic Fibrosis Care Center by the National Cystic Fibrosis Foundation Cystic Fibrosis: Information for Caregivers

More information

Pulmonary Exacerbations:

Pulmonary Exacerbations: Pulmonary Exacerbations: Better Understanding Needed Michael Tracy, MD Clinical Assistant Professor Pediatric Pulmonary CF Pulmonary Exacerbations Definition Importance Causes Treatment Research opportunities

More information

CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION

CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION A Program for the CF Center Care Team Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex

More information

Rhianna Cenci, Sodexo Dietetic Intern

Rhianna Cenci, Sodexo Dietetic Intern Rhianna Cenci, Sodexo Dietetic Intern Objectives Overview of CF and Treatments CF Medical Nutrition Therapy CF Case Study Cystic Fibrosis (CF) Overview Inherited chronic disease Produces unusually thick

More information

Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures

Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael

More information